Zenas BioPharma’s (ZBIO) Buy Rating Reaffirmed at HC Wainwright

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $44.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 70.21% from the stock’s current price.

Several other research analysts also recently weighed in on ZBIO. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Wedbush reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Citigroup upped their price objective on shares of Zenas BioPharma from $41.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, September 30th. Morgan Stanley upped their price objective on shares of Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Tuesday, October 6th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $46.71.

Zenas BioPharma Price Performance

Shares of ZBIO traded up $0.99 during mid-day trading on Tuesday, hitting $25.85. 148,403 shares of the company were exchanged, compared to its average volume of 808,853. Zenas BioPharma has a 1-year low of $13.50 and a 1-year high of $44.60. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The company has a 50 day moving average of $30.45 and a 200-day moving average of $25.41. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -2.89 and a beta of -0.90.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. Analysts expect that Zenas BioPharma will post -5.81 EPS for the current fiscal year.

Institutional Trading of Zenas BioPharma

Several large investors have recently bought and sold shares of ZBIO. Quantbot Technologies LP purchased a new stake in shares of Zenas BioPharma in the 2nd quarter valued at approximately $49,000. Jupiter Topco LLC purchased a new stake in shares of Zenas BioPharma in the 2nd quarter valued at approximately $201,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Zenas BioPharma in the 2nd quarter valued at approximately $204,000. Sei Investments Co. purchased a new stake in shares of Zenas BioPharma in the 1st quarter valued at approximately $242,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Zenas BioPharma in the 2nd quarter valued at approximately $329,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.